Coloplast - Capital/Financing Update 2022

Announcement no. 06/2022 - Coloplast announces the successful issuance of EUR 2.2 billion senior notes under its Euro Medium Term Note programme

Coloplast announces the successful issuance of EUR 2.2 billion senior notes under its Euro Medium Term Note programme

NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES. NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO ANY PERSON IN ANY JURISDICTION WHERE RELEASE, PUBLICATION OR DISTRIBUTION TO SUCH PERSON IS RESTRICTED BY ANY LAW OR REGULATION APPLICABLE IN SUCH JURISDICTION.

THIS ANNOUNCEMENT IS NOT AN OFFER TO SELL OR ISSUE OR INVITATION TO PURCHASE OR SUBSCRIBE FOR, OR ANY SOLICITATION OF AN OFFER TO PURCHASE OR SUBSCRIBE FOR, ANY SECURITIES.

Coloplast has today raised EUR 2.2 billion in debt financing through the issuance by Coloplast Finance B.V., a newly formed subsidiary of Coloplast, ("Coloplast Finance") of senior unsecured notes in an aggregate principal amount of EUR 2.2 billion (the "Notes") under the Coloplast Euro Medium Term Note programme (the "EMTN Programme"). The Notes are unconditionally and irrevocably guaranteed by Coloplast.

The key details of the Notes are:

Tranche amount: EUR 650 million

Maturity date: 19 May 2024
Coupon: 3-month Euribor + 75bp
Price: 100.203%
Listing: Nasdaq Copenhagen

Tranche amount: EUR 850 million

Maturity date: 19 May 2027
Coupon: 2.250%
Price: 99.473%
Listing: Nasdaq Copenhagen

Tranche amount: EUR 700 million

Maturity date: 19 May 2030
Coupon: 2.750%
Price: 99.950%
Listing: Nasdaq Copenhagen

The net proceeds to Coloplast Finance from the issuance of the Notes will be made available to Coloplast and applied to the refinancing in full of the term loan facility borrowed by Coloplast to finance its acquisition of Atos Medical which closed on 31 January 2022.

The Base Prospectus in respect of the EMTN Programme approved by the Danish Financial Supervisory Authority (Finanstilsynet) is available on Coloplast's website at Bond Investors (coloplast.com). The Final Terms of the Notes will be available on the website in connection with the settlement of the issuance.

Our mission

Making life easier for people

with intimate health care needs

Our values

Closeness... to better understand

Passion... to make a difference

Respect and responsibility... to guide us

Our vision

Setting the global standard

for listening and responding

For further information, please contact


*Investors and analysts* Ellen Bjurgert Vice President, Investor Relations Tel. +45 4911 1800 /+45 4911 3376 Email: [email protected] Aleksandra Dimovska Director, Investor Relations Tel. +45 4911 1800 /+45 4911 2458 Email: [email protected]	*Press and media* Peter Mønster Sr. Media Relations Manager Tel. +45 4911 2623 Email: [email protected]	*Address* Coloplast A/S Holtedam 1 DK-3050 Humlebaek Denmark Company reg. (CVR) no. 69749917 *Website* www.coloplast.com

This announcement is available in a Danish and an English-language version. In the event of discrepancies, the Danish version shall prevail.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate health care. Our business includes Ostomy Care, Continence Care, Wound and Skin Care, Interventional Urology and Voice & Respiratory Care. We operate globally and employ about 14,000 employees.

Coloplast A/S Investor Relations Comp. reg. (CVR).

Holtedam 1 Tel. +45 4911 1800 69749917

DK-3050 Humlebaek Fax +45 4911 1555

Denmark www.coloplast.com

Attachment